This guy valued CLDA at $37.00 Target Aug 10th 2010
George B. Zavoico, Ph.D., has over 6 years of experience as a life sciences analyst writing research on publicly traded equities. He has most recently worked at Westport Capital Markets and Cantor Fitzgerald in their research departments and has received The Financial Times/Starmine Award two years in a row for being among the top-ranked Earnings Estimators in the Biotechnology Sector. His principal focus is on biotechnology, biopharmaceutical, specialty pharmaceutical, and molecular diagnostics companies engaged in discovering, developing, and marketing drugs and value-added diagnostics for the diagnosis and treatment of cancer and cardiovascular and inflammatory/immune diseases and disorders.
Prior to working as an analyst, Dr. Zavoico established his own consulting company serving the biotech and pharmaceutical industries by providing competitive intelligence and marketing research, due diligence services, and guidance in regulatory affairs. He also wrote extensively on healthcare and the biotech and pharmaceutical industries for periodicals targeting the general public and industry executives. Dr. Zavoico began his career as a Senior Research Scientist at Bristol-Myers Squibb Co., moving on to management positions at Alexion Pharmaceuticals, Inc. and T Cell Sciences, Inc. (now Celldex Therapeutics, Inc.). . He has a B.S. in Biology from St. Lawrence University and Ph.D. in Physiology from the University of Virginia.
